Biotechnology Today
more-
Eliem drops depression drug, ending pursuit of Biogen-Sage and laying off 55% of team
How many years of cash runway do biotechs need to feel comfortable? Two? Three? Eliem…
‘Expect us to act’ on M&A, AbbVie CEO says as company plots post-Humira plans
Despite rapidly emptying pipeline, AstraZeneca stays loyal to vaccine, immune therapy business
GE HealthCare snaps up ultrasound AI maker Caption Health
Vistagen, jittery after seeing rivals fail, pauses plan to restart phase 3 anxiety trial pending FDA talks
Markets
more-
Weekly Market Review – March 18, 2023
Stock Markets The major indexes closed mixed for the week. According to the Wall Street…
Bio Space
more
Abbott offers $890M for artery-cleaning device maker Cardiovascular Systems
Abbott already churns out a variety of catheters, stents, imaging…
Magenta’s C-suite heads out the door with 85% of staff as closing process gets underway
Last week, Magenta Therapeutics announced plans to close down. This…
AstraZeneca deals another blow to IL-12, dumping therapy to follow BMS, Merck KGaA out of race
Big Pharma involvement in IL-12 is fading fast. Days after…
Global News
more
SpaceX Starlink wins permit to send internet to customers like you
SpaceX has been busy building its Starlink satellite constellation. To…
Facebook video calls soar 1000% during Italy’s lockdown
Facebook has seen usage across its platforms surge in countries…
WeWork board’s special committee is demanding that SoftBank follow through with investment
Five months after SoftBank agreed to a massive bailout of…
Eliem drops depression drug, ending pursuit of Biogen-Sage and laying off 55% of team
‘Expect us to act’ on M&A, AbbVie CEO says as company plots post-Humira plans
Despite rapidly emptying pipeline, AstraZeneca stays loyal to vaccine, immune therapy business
GE HealthCare snaps up ultrasound AI maker Caption Health
Abbott offers $890M for artery-cleaning device maker Cardiovascular Systems
Magenta’s C-suite heads out the door with 85% of staff as closing process gets underway
AstraZeneca deals another blow to IL-12, dumping therapy to follow BMS, Merck KGaA out of race
Surmodics lays off 13% of staff after FDA shoots down drug-coated balloon
Vistagen, jittery after seeing rivals fail, pauses plan to restart phase 3 anxiety trial pending FDA talks
BIO: Big Pharma offers menu of partnering options, but biotechs want licensing entrée